Sanara MedTech (SMTI) Cost of Revenue (2010 - 2026)

Sanara MedTech (SMTI) has 16 years of Cost of Revenue data on file, last reported at $1.9 million in Q1 2026.

• Quarterly Cost of Revenue rose 4.83% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (down 5.88% YoY) and the FY2025 annual result came in at $7.5 million, down 7.6% from the prior year.
• Cost of Revenue grew to $1.9 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $2.4 million in Q4 2022 to a low of $805081.0 in Q1 2022.
• A 5-year average of $1.9 million and a median of $1.9 million in 2026 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue soared 330.55% — and 2023, when it declined 24.52%.
• Tracing SMTI's Cost of Revenue over 5 years: stood at $2.4 million in 2022, then decreased by 24.52% to $1.8 million in 2023, then gained by 25.78% to $2.2 million in 2024, then slipped by 16.66% to $1.9 million in 2025, then rose by 2.62% to $1.9 million in 2026.
• The last three Cost of Revenue figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.